Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new...
-
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...
-
Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
-
New York, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- ThinkLabs, an AI-powered grid intelligence company that empowers critical infrastructure with trustworthy, physics-informed AI, announced today...
-
Press ReleaseDanish version attached Trifork Digital Health expands into new markets with engagements in Canada and Germany Aarhus, Denmark – March 31, 2026 Trifork Digital Health is expanding its...
-
Standing Ovation, a French precision fermentation pioneer producing next-generation proteins, has announced a $34.2 million (€30 million) Series B round.
-
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) --...
-
2026 report evaluating Hume Health Hume Body Pod accuracy claims, review of 98% DEXA details, 45+ metrics vs. leading bathroom scales.
-
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP examines the adequacy of Snowflake Inc.'s (NYSE: SNOW) risk disclosures during the period June 27, 2023 through February 28,...
-
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...